Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment With Pomalidomide-Dexamethasone.

MLA

Cerchione, Claudio, et al. “Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment With Pomalidomide-Dexamethasone.” Clinical Lymphoma, Myeloma & Leukemia, vol. 19, Oct. 2019, p. e358. EBSCOhost, https://doi.org/10.1016/j.clml.2019.09.591.

APA

Cerchione, C., Martinelli, G., Nappi, D., Pareto, A. E., Di Perna, M., Ronconi, S., Pane, F., & Catalano, L. (2019). Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment With Pomalidomide-Dexamethasone. Clinical Lymphoma, Myeloma & Leukemia, 19, e358. https://doi.org/10.1016/j.clml.2019.09.591

Chicago

Cerchione, Claudio, Giovanni Martinelli, Davide Nappi, Anna Emanuele Pareto, Maria Di Perna, Sonia Ronconi, Fabrizio Pane, and Lucio Catalano. 2019. “Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment With Pomalidomide-Dexamethasone.” Clinical Lymphoma, Myeloma & Leukemia 19 (October): e358. doi:10.1016/j.clml.2019.09.591.